• Spanish health authorities grant regulatory approval for Sativex®, the first new treatment for MS-related spasticity in decades • Launch expected 4th Quarter 2010 • Application submitted unde... more
Porton Down, UK, 27 July 2010: GW Pharmaceuticals plc (AIM: GWP) today announces the appointment of Tom Lynch as a non-executive director with immediate effect.... more
In response to a story in a regional UK media outlet yesterday, GW wishes to make the following clarification: ... more
London, UK; Tokyo, Japan; June 30 2010: GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announce that they have signed a three year extension to their global cannabinoid re... more
Porton Down, UK, 22 June 2010: GW Pharmaceuticals plc (AIM: GWP) announces that its Managing Director, Justin Gover will be presenting at the 5th Annual Piper Jaffray Europe Healthcare Conference in L... more
Porton Down, UK, 21 June 2010: GW Pharmaceuticals plc (GWP:AIM) today announces the UK launch of Sativex®, its Oromucosal Spray for the treatment of spasticity due to Multiple Sclerosis (MS). Sativex®... more
Porton Down, UK, 20 May 2010: GW Pharmaceuticals plc (AIM: GWP), the specialty pharmaceutical company focused on cannabinoid science, announces its interim results for the six months ended 31 March 20... more
Porton Down, UK; 23 March 2010: GW Pharmaceuticals plc (AIM: GWP) today announced preliminary results of a Phase IIb dose-ranging trial evaluating the efficacy and safety of Sativex® in the treatment ... more
Porton Down, UK, 18 March 2010: GW Pharmaceuticals plc (GWP:AIM) today provides an update on the progress of its regulatory submission for Sativex® Oromucosal Spray for the treatment of the symptoms o... more
